CXCL12 and DPP4

Number of citations of the paper that reports this interaction (PubMedID 11390394)
71

Data Source:
HPRD (in vitro)

		CXCL12	DPP4
Description		C-X-C motif chemokine ligand 12	dipeptidyl peptidase 4
Image
GO Annotations	Cellular Component	Extracellular Region Nucleus Cytoplasm External Side Of Plasma Membrane Collagen-containing Extracellular Matrix Extracellular Exosome	Extracellular Region Lysosomal Membrane Plasma Membrane Focal Adhesion Cell Surface Membrane Integral Component Of Membrane Apical Plasma Membrane Lamellipodium Endocytic Vesicle Lamellipodium Membrane Membrane Raft Intercellular Canaliculus Extracellular Exosome
	Molecular Function	Signaling Receptor Binding Integrin Binding Protein Binding Chemokine Activity Growth Factor Activity Chemokine Receptor Binding CXCR Chemokine Receptor Binding	Virus Receptor Activity Protease Binding Aminopeptidase Activity Serine-type Endopeptidase Activity Signaling Receptor Binding Protein Binding Serine-type Peptidase Activity Dipeptidyl-peptidase Activity Identical Protein Binding Protein Homodimerization Activity Chemorepellent Activity
	Biological Process	Response To Hypoxia Neuron Migration Positive Regulation Of Endothelial Cell Proliferation Cellular Calcium Ion Homeostasis Chemotaxis Defense Response Immune Response Cell Adhesion Signal Transduction G Protein-coupled Receptor Signaling Pathway Axon Guidance Blood Circulation Regulation Of Actin Polymerization Or Depolymerization Adult Locomotory Behavior Response To Radiation Response To Heat Response To Virus Telencephalon Cell Migration Positive Regulation Of Cell Migration Animal Organ Regeneration Positive Regulation Of Dopamine Secretion Integrin Activation Chemokine (C-X-C Motif) Ligand 12 Signaling Pathway Response To Peptide Hormone Positive Regulation Of Neuron Differentiation Positive Regulation Of Cell Adhesion Positive Regulation Of Axon Extension Involved In Axon Guidance Induction Of Positive Chemotaxis Detection Of Temperature Stimulus Involved In Sensory Perception Of Pain Detection Of Mechanical Stimulus Involved In Sensory Perception Of Pain Cell Chemotaxis Chemokine-mediated Signaling Pathway Positive Regulation Of Monocyte Chemotaxis Positive Regulation Of Calcium Ion Import Negative Regulation Of Intrinsic Apoptotic Signaling Pathway In Response To DNA Damage Negative Regulation Of Leukocyte Tethering Or Rolling Response To Ultrasound Cellular Response To Chemokine Positive Regulation Of T Cell Migration Negative Regulation Of Dendritic Cell Apoptotic Process	Behavioral Fear Response Response To Hypoxia Proteolysis Cell Adhesion Positive Regulation Of Cell Population Proliferation Negative Regulation Of Extracellular Matrix Disassembly T Cell Costimulation Regulation Of Cell-cell Adhesion Mediated By Integrin Locomotory Exploration Behavior Psychomotor Behavior T Cell Activation Endothelial Cell Migration Viral Entry Into Host Cell Regulation Of Insulin Secretion Negative Chemotaxis Negative Regulation Of Neutrophil Chemotaxis
Pathways		Nuclear signaling by ERBB4 Signaling by ROBO receptors Chemokine receptors bind chemokines G alpha (i) signalling events Estrogen-dependent gene expression	Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
Drugs		CTCE-0214 Tinzaparin	Atorvastatin Sitagliptin 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One 5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine (2s)-Pyrrolidin-2-Ylmethylamine 4-Iodo-L-phenylalanine Diisopropylphosphono Group 1-(1-phenylcyclopentyl)methylamine (S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide Vildagliptin PSN9301 AMG-222 Bisegliptin Alogliptin Saxagliptin (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE (2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine (2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine (3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine (7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amine (2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE (1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE (2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE (2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE (2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE 4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide (2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine 7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile 4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE 1-biphenyl-2-ylmethanamine (1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile (2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE (4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE (3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE 1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE ABT-341 (2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE (3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE Gosogliptin N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide (3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE 6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM 7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE 2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE 4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE 2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE Linagliptin Dutogliptin
Diseases
GWAS		Anti-drug antibodies in autoimmune disease (time to event) ( 33125391) Blood protein levels ( 30072576) Body mass index ( 25760438) Coronary artery disease ( 32469254 26708285 24262325 26343387) Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) ( 28714975) Coronary heart disease ( 17634449 21378990) Diastolic blood pressure ( 27841878) Eosinophil counts ( 32888494) Eosinophil percentage of white cells ( 32888494) Granulocyte count ( 27863252) Hematocrit ( 32888494) Hemoglobin ( 32888494) Left superior temporal gyrus thickness (schizophrenia interaction) ( 26249676) Lymphocyte counts ( 32888494) Monocyte count ( 32888494 27863252) Myeloid white cell count ( 27863252) Myocardial infarction ( 33532862 26343387) Myocardial infarction (early onset) ( 19198609) Neutrophil count ( 32888494 27863252) QT interval (ambient particulate matter interaction) ( 28749367) Red blood cell count ( 32888494) Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous) ( 28628665) Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) ( 24554482) Schizophrenia ( 23212062) Smoking initiation (ever regular vs never regular) ( 31089300) Sum basophil neutrophil counts ( 27863252) Sum neutrophil eosinophil counts ( 27863252) White blood cell count ( 32888494 27863252)	Asthma ( 32296059) Asthma with severe exacerbations ( 32841424) Blood osmolality (transformed sodium) ( 28360221) Brain morphology (min-P) ( 32665545) Brain morphology (MOSTest) ( 32665545) Cognitive ability ( 29186694) Cognitive ability (MTAG) ( 29186694) Cortical surface area (MOSTest) ( 32665545) Cortical thickness (MOSTest) ( 32665545) Dentate gyrus molecular layer volume ( 30279459) General cognitive ability ( 29844566) Hippocampal tail volume ( 30279459) Hippocampal tail volume (corrected for total hippocampal volume) ( 30279459) Hippocampal volume ( 22504421) Intelligence (MTAG) ( 29326435) Multiple sclerosis ( 31604244) Reaction time ( 29844566) Regular attendance at a pub or social club ( 29970889) Rheumatoid arthritis ( 24782177) Schizophrenia ( 25056061 29483656) Smoking initiation (ever regular vs never regular) ( 30679032) Smoking status (ever vs never smokers) ( 30643258) Subcortical volume (min-P) ( 32665545) Subcortical volume (MOSTest) ( 32665545) Subiculum volume ( 30279459) Total hippocampal volume ( 30279459) Tourette syndrome ( 30818990)
Interacting Genes		32 interacting genes: CCL11 CCL13 CCL20 CCL21 CCL25 CCL26 CCL28 CCL5 CD4 CTSG CXCL10 CXCL11 CXCL14 CXCL17 CXCL2 CXCL6 CXCL9 CXCR4 DAZAP2 DPP4 ELANE FBXO7 FN1 MMP2 NIF3L1 PF4 PF4V1 PPBP RPS6KA1 VCAN XCL1 XCL2	16 interacting genes: ADA CCL11 CCL22 CCL3L1 CCL5 CD4 CPAMD8 CXCL10 CXCL11 CXCL12 CXCL9 CXCR4 DKK1 FAP GRP PTPRC
Entrez ID		6387	1803
HPRD ID		02904	02187
Ensembl ID		ENSG00000107562	ENSG00000197635
Uniprot IDs		P48061	P27487
PDB IDs		1A15 1QG7 1SDF 1VMC 2J7Z 2K01 2K03 2K04 2K05 2KEC 2KED 2KEE 2KOL 2N55 2NWG 2SDF 3GV3 3HP3 4LMQ 4UAI 6SHR	1J2E 1N1M 1NU6 1NU8 1PFQ 1R9M 1R9N 1RWQ 1TK3 1TKR 1U8E 1W1I 1WCY 1X70 2AJL 2BGN 2BGR 2BUB 2FJP 2G5P 2G5T 2G63 2HHA 2I03 2I78 2IIT 2IIV 2JID 2OAG 2OGZ 2OLE 2ONC 2OPH 2OQI 2OQV 2P8S 2QJR 2QKY 2QOE 2QT9 2QTB 2RGU 2RIP 3BJM 3C43 3C45 3CCB 3CCC 3D4L 3EIO 3F8S 3G0B 3G0C 3G0D 3G0G 3H0C 3HAB 3HAC 3KWF 3KWJ 3NOX 3O95 3O9V 3OC0 3OPM 3Q0T 3Q8W 3QBJ 3SWW 3SX4 3VJK 3VJL 3VJM 3W2T 3WQH 4A5S 4DSA 4DSZ 4DTC 4G1F 4J3J 4JH0 4KR0 4L72 4LKO 4N8D 4N8E 4PNZ 4PV7 4QZV 5I7U 5ISM 5J3J 5KBY 5T4B 5T4E 5T4F 5T4H 5Y7H 5Y7J 5Y7K 5ZID 6B1E 6B1O
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?